CTLA4 and neoplasm: The unexpected clinical success of immunotherapy by targeting the immune system using immune checkpoint inhibitors like anti-PD1- and/or anti-CTLA4 antibody in different tumor entities has proven the importance of tumor immune cell interactions within the tumor microenvironment [12].